Limits...
Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.

Yoda T, McNamara KM, Miki Y, Takagi M, Rai Y, Ohi Y, Sagara Y, Tamaki K, Hirakawa H, Ishida T, Suzuki T, Ohuchi N, Sasano H - Cancer Sci. (2014)

Bottom Line: Invasive lobular carcinoma (ILC) accounts for approximately 10% of all breast carcinomas and is characterized by higher levels of androgen receptor (AR) compared to invasive ductal carcinoma (IDC).In ILC cases the status of 5αRed1 and 17βHSD5 was inversely correlated with tumor size (P = 0.0053) and nuclear grade (P = 0.0290), and significantly associated with better overall survival of the patients (P = 0.0059).Results of our present study indicated that androgen-producing enzymes could play pivotal protective roles in AR-enriched ILC cases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Tohoku University Graduate School of Medicine, Sendai.

Show MeSH

Related in: MedlinePlus

Representative illustrations of androgen receptor (AR), 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5), and 5α-Reductase type 1 (5αRed1) immunohistochemistry in AR+/17βHSD5+/5αRed1+ (b–d) and AR−/17βHSD5−/5αRed1− (f–h) invasive lobular carcinoma cases. Hematoxylin–eosin staining (a,e). Androgen receptor was immunolocalized in the nuclei of carcinoma cells (b,f), and 17βHSD5 (c,g) and 5αRed1 (d,h) immunolocalized in the cytoplasm of carcinoma cells. Scale bar = 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4462384&req=5

fig01: Representative illustrations of androgen receptor (AR), 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5), and 5α-Reductase type 1 (5αRed1) immunohistochemistry in AR+/17βHSD5+/5αRed1+ (b–d) and AR−/17βHSD5−/5αRed1− (f–h) invasive lobular carcinoma cases. Hematoxylin–eosin staining (a,e). Androgen receptor was immunolocalized in the nuclei of carcinoma cells (b,f), and 17βHSD5 (c,g) and 5αRed1 (d,h) immunolocalized in the cytoplasm of carcinoma cells. Scale bar = 100 μm.

Mentions: Androgen receptor immunoreactivity was detected in the nuclei of tumor cells, and 17βHSD5 and 5αRed1 immunoreactivity in the cytoplasm of tumor cells (Fig. 1). Androgen receptor was highly prevalent with positive nuclei detected in almost all the carcinoma cells in ILC. In ILC, AR-positive cases (defined as >10% LI) were 97.8% (174 cases out of 178) and the mean value of AR LI was 90.6 ± 1.4 (range, 0–100%). The proportion of 17βHSD5- and 5αRed1-positive cases (defined as >50% tumor cells of cytoplasmic immunoreactivity) were 61.8% and 53.4%, respectively, with 34.8% double-positive for both enzymes.


Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.

Yoda T, McNamara KM, Miki Y, Takagi M, Rai Y, Ohi Y, Sagara Y, Tamaki K, Hirakawa H, Ishida T, Suzuki T, Ohuchi N, Sasano H - Cancer Sci. (2014)

Representative illustrations of androgen receptor (AR), 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5), and 5α-Reductase type 1 (5αRed1) immunohistochemistry in AR+/17βHSD5+/5αRed1+ (b–d) and AR−/17βHSD5−/5αRed1− (f–h) invasive lobular carcinoma cases. Hematoxylin–eosin staining (a,e). Androgen receptor was immunolocalized in the nuclei of carcinoma cells (b,f), and 17βHSD5 (c,g) and 5αRed1 (d,h) immunolocalized in the cytoplasm of carcinoma cells. Scale bar = 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4462384&req=5

fig01: Representative illustrations of androgen receptor (AR), 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5), and 5α-Reductase type 1 (5αRed1) immunohistochemistry in AR+/17βHSD5+/5αRed1+ (b–d) and AR−/17βHSD5−/5αRed1− (f–h) invasive lobular carcinoma cases. Hematoxylin–eosin staining (a,e). Androgen receptor was immunolocalized in the nuclei of carcinoma cells (b,f), and 17βHSD5 (c,g) and 5αRed1 (d,h) immunolocalized in the cytoplasm of carcinoma cells. Scale bar = 100 μm.
Mentions: Androgen receptor immunoreactivity was detected in the nuclei of tumor cells, and 17βHSD5 and 5αRed1 immunoreactivity in the cytoplasm of tumor cells (Fig. 1). Androgen receptor was highly prevalent with positive nuclei detected in almost all the carcinoma cells in ILC. In ILC, AR-positive cases (defined as >10% LI) were 97.8% (174 cases out of 178) and the mean value of AR LI was 90.6 ± 1.4 (range, 0–100%). The proportion of 17βHSD5- and 5αRed1-positive cases (defined as >50% tumor cells of cytoplasmic immunoreactivity) were 61.8% and 53.4%, respectively, with 34.8% double-positive for both enzymes.

Bottom Line: Invasive lobular carcinoma (ILC) accounts for approximately 10% of all breast carcinomas and is characterized by higher levels of androgen receptor (AR) compared to invasive ductal carcinoma (IDC).In ILC cases the status of 5αRed1 and 17βHSD5 was inversely correlated with tumor size (P = 0.0053) and nuclear grade (P = 0.0290), and significantly associated with better overall survival of the patients (P = 0.0059).Results of our present study indicated that androgen-producing enzymes could play pivotal protective roles in AR-enriched ILC cases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Tohoku University Graduate School of Medicine, Sendai.

Show MeSH
Related in: MedlinePlus